ASP3026 had a cell proliferation IC50 of 19 nM in K299 cells after 72 hours. In the PfLysRS ATP hydrolysis assay, its IC50 was 965 nM. In SU-DHL-1 cells, the MTS viability IC50 was 0.4 μM after 48 h. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell proliferation in K299
Cell-based study · K299 [1]
K299 cells were exposed to serial dilutions of ASP3026 for 72 hours. The cell proliferation IC50 was 19 nM.
Literature-Reported Treatment Conditions
- Exposure duration
- 72 hours
- Method
- in the presence of serial dilutions of compounds
- Vehicle
- 0.5% final DMSO concentration
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: ASP3026
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
METHODS > Proliferation assay (S121, S122, S124, S125); Table 1 (T1.h1, T1.r1)
cell proliferation rate: cell proliferation rate; comparator: vehicle-treated control — METHODS > Proliferation assay (S121, S124); Table 1 (T1.h1, T1.r1)
ATP hydrolysis in a PfLysRS assay
Cell-based study · PfLysRS [2]
PfLysRS was incubated with ASP3026 and assessed using an ATP hydrolysis assay. The IC50 was 965 nM.
Literature-Reported Treatment Conditions
- Exposure duration
- mixed with compounds and incubated for 10 min. Then 5 μL substrate mixture (2 μM ATP, 10 μM l-lysine and 31 nM pyrophosphatase) was added to start the reaction at 37 °C and incubated for 6 h.
- Method
- mixed with compounds
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: ASP3026
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Substitution of the 4-(4-methylpiperazinyl)piperidinyl moiety significantly improved the selectivity against PfLysRS in vitro (S24); Methods > ATP hydrolysis assays (S152, S156, S157, S160)
ATP hydrolysis assays: ATP hydrolysis assays; comparator: DMSO was added into negative control wells and l-lysine was removed in positive control wells — Results > Substitution of the 4-(4-methylpiperazinyl)piperidinyl moiety significantly improved the selectivity against PfLysRS in vitro (S24); Methods > ATP hydrolysis assays (S152)
Cell viability in SU-DHL-1
Cell-based study · SU-DHL-1 [3]
SU-DHL-1 cells were treated with the compound for 48 h and assessed using an MTS viability assay. The IC50 was 0.4 μM.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h
- Vehicle
- DMSO admixed with H2O and HCl (1:1)
- Reported limits
- Not stated in the sentences used: dose, route.
Methods and source locations
Compound reported in the paper: ASP3026
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > ASP3026 decreases NPM-ALK+ ALCL cell viability (S1, S3, S4); METHODS > ALK inhibitor (S58); METHODS > MTS assay (S61)
viability of all NPM-ALK+ ALCL cell lines tested, as measured by MTS assay: viability of all NPM-ALK+ ALCL cell lines tested, as measured by MTS assay; comparator: T lymphocytes that were used as a negative control — RESULTS > ASP3026 decreases NPM-ALK+ ALCL cell viability (S1, S3)